Assessment of the Association of HIV Infection with Hepatic Steatosis or Fibrosis: a Cross-Sectional, Case-Control Study
Abstract <jats:underline>Background</jats:underline>: Human immunodeficiency virus (HIV) infection and antiretroviral therapy have been associated with non-alcoholic fatty liver disease (NAFLD), but few studies have evaluated whether HIV infection is an independent risk factor for the development of hepatic steatosis and advanced liver fibrosis. <jats:underline>Objectives</jats:underline>: To study the prevalence and severity of hepatic steatosis and advanced fibrosis in people living with HIV and control outpatients. <jats:underline>Methods</jats:underline>: We conducted a cross-sectional analysis of relevant data from 875 pairs of individuals belonging to an HIV-dedicated outpatient clinic and an adult primary care clinic of an inner-city hospital. Hepatic Steatosis Index (HSI) and FIB-4 index were calculated as non-invasive measures of steatosis and fibrosis, respectively. A multivariate logistic regression analysis was performed to assess predictors of steatosis and advanced fibrosis. Results: The prevalence of hepatic steatosis, determined by HSI ≥36, was higher in HIV-negative subjects (71.5% vs. 65.4%, p=0.006). The prevalence of advanced fibrosis, determined by FIB-4 index ≥3.25, was higher in the HIV-positive group (7% vs. 1.7%, p <0.001). Multivariable analysis did not identify HIV infection to be an independent risk factor for hepatic steatosis (p=0.068) and advanced fibrosis. <jats:underline>Conclusions</jats:underline>: In this cohort, hepatic steatosis was more prevalent in non-HIV infected patients, while advanced fibrosis had a higher prevalence in people living with HIV. HIV infection was not found to be an independent risk factor for either hepatic steatosis or fibrosis..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ResearchSquare.com - (2022) vom: 29. Juli Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Debroy, Paula [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-237921/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA033519366 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA033519366 | ||
| 003 | DE-627 | ||
| 005 | 20230429192403.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220113s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-237921/v1 |2 doi | |
| 035 | |a (DE-627)XRA033519366 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-237921/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Debroy, Paula |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessment of the Association of HIV Infection with Hepatic Steatosis or Fibrosis: a Cross-Sectional, Case-Control Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract <jats:underline>Background</jats:underline>: Human immunodeficiency virus (HIV) infection and antiretroviral therapy have been associated with non-alcoholic fatty liver disease (NAFLD), but few studies have evaluated whether HIV infection is an independent risk factor for the development of hepatic steatosis and advanced liver fibrosis. <jats:underline>Objectives</jats:underline>: To study the prevalence and severity of hepatic steatosis and advanced fibrosis in people living with HIV and control outpatients. <jats:underline>Methods</jats:underline>: We conducted a cross-sectional analysis of relevant data from 875 pairs of individuals belonging to an HIV-dedicated outpatient clinic and an adult primary care clinic of an inner-city hospital. Hepatic Steatosis Index (HSI) and FIB-4 index were calculated as non-invasive measures of steatosis and fibrosis, respectively. A multivariate logistic regression analysis was performed to assess predictors of steatosis and advanced fibrosis. Results: The prevalence of hepatic steatosis, determined by HSI ≥36, was higher in HIV-negative subjects (71.5% vs. 65.4%, p=0.006). The prevalence of advanced fibrosis, determined by FIB-4 index ≥3.25, was higher in the HIV-positive group (7% vs. 1.7%, p <0.001). Multivariable analysis did not identify HIV infection to be an independent risk factor for hepatic steatosis (p=0.068) and advanced fibrosis. <jats:underline>Conclusions</jats:underline>: In this cohort, hepatic steatosis was more prevalent in non-HIV infected patients, while advanced fibrosis had a higher prevalence in people living with HIV. HIV infection was not found to be an independent risk factor for either hepatic steatosis or fibrosis. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Nagraj, Sanjana |e verfasserin |4 aut | |
| 700 | 1 | |a Chamorro-Pareja, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Castro, Neva |e verfasserin |4 aut | |
| 700 | 1 | |a de Leon, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Guerson-Gil, Arcelia |e verfasserin |4 aut | |
| 700 | 1 | |a Quintero, Orlando |e verfasserin |4 aut | |
| 700 | 1 | |a Laniado, Isaac |e verfasserin |4 aut | |
| 700 | 1 | |a Kladas, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Desai, Dimpi |e verfasserin |4 aut | |
| 700 | 1 | |a Mathias, Priyanka |e verfasserin |4 aut | |
| 700 | 1 | |a Leider, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Kishore, Preeti |e verfasserin |4 aut | |
| 700 | 1 | |a Palaiodimos, Leonidas |e verfasserin |4 aut | |
| 700 | 1 | |a Kotler, Donald P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2022) vom: 29. Juli |
| 773 | 1 | 8 | |g year:2022 |g day:29 |g month:07 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s42399-021-01054-4 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-237921/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 29 |c 07 | ||